» Articles » PMID: 21165538

Brain Metastasis in Lung Cancer. Comparison of Cerebral MRI and 18F-FDG-PET/CT for Diagnosis in the Initial Staging

Overview
Journal Nuklearmedizin
Publisher Thieme
Specialty Nuclear Medicine
Date 2010 Dec 18
PMID 21165538
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: FDG-PET/CT is increasingly used in staging of lung cancer as single "one stop shop" method. AIM, PATIENTS, METHODS: We prospectively included 104 neurological asymptomatic patients (65 years, 26% women) with primary diagnosis of lung cancer. In all patients PET/CT including cerebral imaging and cerebral MRI were performed.

Results: Diagnosis of brain metastases (BM) was made by PET/CT in 8 patients only (7.7%), by MRI in 22 (21.2%). In 80 patients both PET/CT and MRI showed no BM. In 6 patients (5.8%) BM were detectable on PET/CT as well as on MRI. Exclusive diagnosis of BM by MRI with negative finding on PET/CT was present in 16 patients (15.4%). 2 patients (1.9%) had findings typical for BM on PET/CT but were negative on MRI. With MRI overall 100 BM were detected, with PET/CT only 17 BM (p < 0.01). For the diagnosis of BM PET/CT showed a sensitivity of 27.3%, specificity of 97.6%, positive predictive value of 75% and negative predictive value of 83.3%. BM diameter on PET/CT and MRI were consistent in 43%, in 57% BM were measured larger on MRI.

Discussion: Compared to the gold standard of MRI for cerebral staging a considerable number of patients are falsely diagnosed as free from BM by PET/CT. MRI is more accurate than PET/CT for detecting multiple and smaller BM.

Conclusion: In patients with a curative option MRI should be performed additionally to PET/CT for definitive exclusion of brain metastases.

Citing Articles

The value of whole-body MRI instead of only brain MRI in addition to 18 F-FDG PET/CT in the staging of advanced non-small-cell lung cancer.

Holmstrand H, Lindskog M, Sundin A, Hansen T Cancer Imaging. 2025; 25(1):30.

PMID: 40069778 PMC: 11895332. DOI: 10.1186/s40644-025-00852-6.


[Clinical Practice Guidelines for the Management of Brain Metastases from 
Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition)].

Zhongguo Fei Ai Za Zhi. 2025; 28(1):1-21.

PMID: 39763097 PMC: 11848629. DOI: 10.3779/j.issn.1009-3419.2024.102.42.


Clinical features and molecular genetics associated with brain metastasis in suspected early-stage non-small cell lung cancer.

Kim K, Lee J, Lee J, Yong S, Kim E, Jung J Front Oncol. 2023; 13:1148475.

PMID: 37139160 PMC: 10150586. DOI: 10.3389/fonc.2023.1148475.


The Role of Molecular Imaging in Patients with Brain Metastases: A Literature Review.

Urso L, Bonatto E, Nieri A, Castello A, Maffione A, Marzola M Cancers (Basel). 2023; 15(7).

PMID: 37046845 PMC: 10093739. DOI: 10.3390/cancers15072184.


PET-CT in Clinical Adult Oncology-V. Head and Neck and Neuro Oncology.

Wiggins R, Hoffman J, Fine G, Covington M, Salem A, Koppula B Cancers (Basel). 2022; 14(11).

PMID: 35681709 PMC: 9179458. DOI: 10.3390/cancers14112726.